A Retrospective Cohort Study of Multiple Immune-Related Adverse Events and Clinical Outcomes Among Patients With Cancer Receiving Immune Checkpoint Inhibitors

A Retrospective Cohort Study of Multiple Immune-Related Adverse Events and Clinical Outcomes Among Patients With Cancer Receiving Immune Checkpoint Inhibitors

Background and Objectives Immune checkpoint inhibitors (ICIs) are effective in various types of cancer and cause immune-related adverse events (irAEs). The occurrence of irAEs is associated with improved survival outcome. We investigated the association between the occurrence of irAEs and overall su...

Deskribapen osoa

Xehetasun bibliografikoak
Egile Nagusiak:	Hiroki Hata MS, Chikako Matsumura PhD, Yugo Chisaki PhD, Kae Nishioka, Misaki Tokuda, Kazuyo Miyagi, Tomoki Suizu MS, Yoshitaka Yano PhD
Formatua:	Artikulua
Hizkuntza:	English
Argitaratua:	SAGE Publishing 2022-09-01
Saila:	Cancer Control
Sarrera elektronikoa:	https://doi.org/10.1177/10732748221130576

Antzeko izenburuak

Factors Associated With Efficacy and Nivolumab-Related Interstitial Pneumonia in Non-Small Cell Lung Cancer: A Retrospective Survey
nork: Hiroki Hata MS, et al.
Argitaratua: (2020-12-01)

Myocardial Vasculitis Associated With the Immune Checkpoint Inhibitor Pembrolizumab
nork: Hideo Oishi, MD, et al.
Argitaratua: (2020-10-01)

Cancer Immune Checkpoint Inhibitor Therapy and the Gut Microbiota
nork: Arthur E. Frankel MD, et al.
Argitaratua: (2019-04-01)

Desensitizing Effect of Cancer Cachexia on Immune Checkpoint Inhibitors in Patients With Advanced NSCLC
nork: Taichi Miyawaki, MD, et al.
Argitaratua: (2020-06-01)

Inflammatory and immune checkpoint markers are associated with the severity of aortic stenosisCentral MessagePerspective
nork: Bilguun Erkhem-Ochir, MD, et al.
Argitaratua: (2021-03-01)

Noninvasive Imaging of Immune Checkpoint Ligand PD-L1 in Tumors and Metastases for Guiding Immunotherapy
nork: Samit Chatterjee PhD, et al.
Argitaratua: (2017-07-01)

Overcoming Immunotherapy Resistance With Radiation Therapy and Dual Immune Checkpoint Blockade
nork: Tara Davidson, MD, et al.
Argitaratua: (2022-07-01)

Patients With BRAF-Mutant NSCLC May Not Benefit From Immune Checkpoint Inhibitors: A Population-Based Study
nork: Chenxing Zhang, PhD, et al.
Argitaratua: (2020-03-01)

Effectiveness and Safety of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in Pulmonary Sarcomatoid Carcinoma
nork: Daisuke Hazama, MD, PhD, et al.
Argitaratua: (2024-01-01)

A Case of Lung Cancer with Very-Late-Onset Immune Checkpoint Inhibitor-Related MyocarditisNovel Teaching Points
nork: Tatsuya Nishikawa, MD, PhD, et al.
Argitaratua: (2022-07-01)

A Real-World Analysis of Immune Checkpoint Inhibitor-Based Therapy After Osimertinib Treatment in Patients With EGFR-Mutant NSCLC
nork: Kenji Morimoto, MD, PhD, et al.
Argitaratua: (2022-09-01)

Late-Onset Giant Cell Myocarditis Due to Enterovirus During Treatment With Immune Checkpoint Inhibitors
nork: Mariana Mirabel, MD, PhD, et al.
Argitaratua: (2020-09-01)

A Modified Method for the Quantification of Immune Checkpoint Ligands on Exosomes from Human Serum using Flow Cytometry
nork: Alan Guillermo Alejandre Gonzalez PhD, et al.
Argitaratua: (2023-05-01)

A Common Pituitary Autoantibody in Two Patients with Immune Checkpoint Inhibitor-Mediated Hypophysitis: ZCCHC8
nork: Amanda Leiter, MD, MSCR, et al.
Argitaratua: (2020-07-01)

Multicenter, Retrospective Study to Evaluate Necitumumab Plus Cisplatin and Gemcitabine After Immune Checkpoint Inhibitors in Advanced Squamous Cell Lung Cancer in Japan: The NINJA Study
nork: Yasunori Murata, MD, PhD, et al.
Argitaratua: (2023-12-01)

The Use of Herbal Medicine and Dietary Supplements in Cancer Patients Receiving Immune Checkpoint Inhibitors: A Multicenter Cross-Sectional Study
nork: Fatih Kus MD, et al.
Argitaratua: (2024-09-01)

Heterogeneous Outcomes of Immune Checkpoint Inhibitor Rechallenge in Patients With NSCLC: A Systematic Review and Meta-Analysis
nork: Shiting Xu, MD, et al.
Argitaratua: (2022-04-01)

Predictive Impact of Diffuse Positivity for TTF-1 Expression in Patients Treated With Platinum-Doublet Chemotherapy Plus Immune Checkpoint Inhibitors for Advanced Nonsquamous NSCLC
nork: Yuto Terashima, MD, et al.
Argitaratua: (2023-11-01)

Overview of Current Progress in Immune Checkpoint Inhibitor Therapy for Advanced Hepatocellular Carcinoma
nork: Xinlun Dai MD, et al.
Argitaratua: (2020-08-01)

Immune Checkpoint Inhibitor Plus Chemotherapy as First-Line Treatment for Advanced Gastric or Gastroesophageal Junction Cancer: A Systematic Review and Meta-Analysis
nork: Lianghui Zhang MS, et al.
Argitaratua: (2024-08-01)

A Comprehensive Study on the Prognostic Value and Clinicopathological Significance of Different Immune Checkpoints in Patients With Colorectal Cancer: A Systematic Review and Meta-Analysis
nork: Mahdieh Azizi, PhD, et al.
Argitaratua: (2024-01-01)

Identification of Novel Cuproptosis-Related Genes Mediating the Prognosis and Immune Microenvironment in Cholangiocarcinoma
nork: Qiang Liu PhD, et al.
Argitaratua: (2024-04-01)

Comprehensive Characterization of Cardiac, Skeletal and Diaphragmatic Myotoxicity Using CMR in Patients with Immune Checkpoint Inhibitor Therapy and Relation to Outcomes
nork: Etienne Charpentier, MD, et al.
Argitaratua: (2024-01-01)

Dosimetric Modeling of Lymphopenia in Patients With Metastatic Cancer Receiving Palliative Radiation and PD-1 Immune Checkpoint Inhibitors
nork: Jack M. Qian, MD, et al.
Argitaratua: (2022-03-01)

Impact of Immune Checkpoint Inhibitors and Local Radical Treatment on Survival Outcomes in Synchronous Oligometastatic NSCLC
nork: Mandy Jongbloed, MD, et al.
Argitaratua: (2025-03-01)

Cardiac Adverse Events Related to Immune Checkpoint Inhibitors∗
nork: Dorothy M. Gujral, PhD, et al.
Argitaratua: (2020-02-01)

A Retrospective Study on Therapeutic Efficacy of Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors Plus Lenvatinib in Patients With Unresectable Hepatocellular Carcinoma
nork: Ying Teng PhD, et al.
Argitaratua: (2022-03-01)

IgA pemphigus as an immune checkpoint inhibitor-associated skin manifestation
nork: Tristan V.M. Bruijn, MD, et al.
Argitaratua: (2024-05-01)

Synchronous Oligometastasis and Oligoprogression as a Prognostic Marker in Patients With Extensive-Stage SCLC Treated With a Combination of Immune-Checkpoint Inhibitor and Chemotherapy (HOT2301)
nork: Kana Hashimoto, MD, et al.
Argitaratua: (2024-11-01)

IL-23 inhibitor treatment of immune checkpoint inhibitor-associated psoriasis: Case series and review of literature
nork: Natalie Bourand, MS, et al.
Argitaratua: (2025-02-01)

Inhibits Murine Leukemia WEHI-3 Cells and Promotes Immune Response In Vivo
nork: Hsin-Ling Yang PhD, et al.
Argitaratua: (2017-09-01)

Immune Checkpoint Inhibitor Uptake in Real-World Patients With Malignant Pleural Mesothelioma
nork: Roger Y. Kim, MD, et al.
Argitaratua: (2021-06-01)

Kidney Disease Patient Representation in Trials of Combination Therapy With VEGF-Signaling Pathway Inhibitors and Immune Checkpoint Inhibitors: A Systematic Review
nork: Benjamin M.P. Elyan, MBChB, et al.
Argitaratua: (2023-07-01)

Immune Checkpoint Inhibitors in Patients With Cancer and Infection by Hepatitis B or C Virus: A Perspective Through the Results of a European Survey
nork: Marco Tagliamento, MD, et al.
Argitaratua: (2023-01-01)

Lessons From the Development of the Immune Checkpoint Inhibitors in Oncology
nork: Denis L. Jardim MD, PhD, et al.
Argitaratua: (2018-12-01)

Seeking “protective” and “harmful” immune genes during chronic HIV-1 infection by transcriptome analysis
nork: Lingyan Zhu, PhD, et al.
Argitaratua: (2018-09-01)

Immune Checkpoint Inhibitors for the Therapy of Thymoma
nork: Alicia Quilez, MD, et al.
Argitaratua: (2020-03-01)

Characteristics and immune checkpoint inhibitor effects on non-smoking non-small cell lung cancer with KRAS mutation
nork: Jia-Jun Wu, MD, et al.
Argitaratua: (2022-06-01)

The Value of Combined Detection of Megakaryocyte and Platelet Parameters for the Diagnosis of Primary Immune Thrombocytopenia
nork: Weiwei Wang MS, et al.
Argitaratua: (2022-08-01)

Severe recalcitrant cutaneous eruption with dual immune checkpoint blockade
nork: Sakeena Fatima, BA, et al.
Argitaratua: (2018-04-01)